

ARTIFICIAL INTELLIGENCE-ENABLED COMPUTATIONAL PATHOLOGY: FOUNDATION MODELS FOR NEXT-GENERATION PRECISION CANCER DIAGNOSTICS

^{#1}**Dr. Abhishek Narayanan**, Professor, Department of Medical Oncology,
Chettinad Hospital and Research Institute, Chennai, India
Abhisheknarayanan83@gmail.com

Abstract: Computational pathology has emerged as one of the most transformative applications of artificial intelligence (AI) in modern oncology by enabling automated interpretation of whole-slide images, quantitative characterization of tumor biology, and integration of histopathological information with multimodal biomedical data for precision cancer diagnostics. Conventional pathology relies heavily on expert visual interpretation, which, despite its indispensable role in cancer diagnosis, is susceptible to interobserver variability, increasing workload, and limitations in detecting subtle morphological patterns associated with molecular alterations and clinical outcomes. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, and generative artificial intelligence have enabled generalized representation learning across digital pathology, radiological imaging, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes. These intelligent computational systems support precision diagnosis, molecular characterization, biomarker discovery, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen computational pathology by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical intelligence. Despite remarkable technological advances, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interoperability, explainability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of AI-enabled computational pathology, emphasizing foundation models as transformative technologies for next-generation precision cancer diagnostics.[1]

Keywords: *Computational pathology, Foundation models, Artificial intelligence, Digital pathology, Precision oncology, Histopathology, Computational oncology, Clinical decision support, Multi-omics, Personalized medicine.*

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.

1. Introduction

Cancer diagnosis has historically depended upon histopathological examination of tissue specimens, which remains the gold standard for identifying tumor type, grade, stage, and numerous clinically relevant morphological characteristics. Although conventional pathology has achieved remarkable diagnostic accuracy, the increasing complexity of modern oncology demands computational methods capable of

integrating microscopic tissue architecture with molecular biology, imaging, and longitudinal clinical information.[2]

Advances in whole-slide imaging have enabled complete digitization of histopathological specimens, creating unprecedented opportunities for artificial intelligence to analyze billions of cellular structures simultaneously. Modern digital pathology generates high-dimensional spatial information describing cellular morphology, tissue

organization, immune infiltration, stromal remodeling, angiogenesis, fibrosis, necrosis, and tumor heterogeneity at microscopic resolution.[3] Foundation AI models have emerged as transformative computational technologies capable of learning generalized histopathological representations from massive datasets while integrating complementary biomedical information including radiological imaging, multi-omics, laboratory biomarkers, electronic health records, and longitudinal clinical outcomes. This convergence establishes computational pathology as a cornerstone of next-generation precision oncology.

2. Evolution of Computational Pathology

Computational pathology has evolved from traditional image processing algorithms toward intelligent biomedical ecosystems capable of continuously learning from multimodal healthcare data. Early computational methods primarily relied upon handcrafted image features describing cellular morphology, nuclear texture, glandular architecture, and tissue organization. Although these systems demonstrated valuable diagnostic performance, they remained constrained by limited adaptability and handcrafted feature engineering.[4]

Deep learning substantially transformed computational pathology through automated feature extraction from whole-slide images without requiring manual engineering. Convolutional neural networks achieved remarkable success in tumor detection, grading, segmentation, mitosis identification, and prognostic prediction. Transformer architectures subsequently revolutionized computational pathology by learning contextual relationships among billions of histological structures distributed throughout entire tissue specimens.

Foundation AI models now extend these advances through large-scale self-supervised pretraining capable of generating transferable histopathological knowledge applicable across diverse cancer types and clinical applications.[5]

3. Principles of Foundation Models in Computational Pathology

Foundation AI models differ fundamentally from conventional pathology algorithms because they acquire generalized biomedical representations from massive histopathological and multimodal datasets before specialization for individual diagnostic tasks. Rather than learning isolated classification problems, these models develop transferable computational knowledge applicable across diagnosis, prognosis, molecular characterization, biomarker discovery, therapeutic optimization, disease monitoring, and clinical decision support.[6]

Self-supervised learning enables discovery of latent tissue patterns without requiring extensive manual annotation, while multimodal transformer architectures align digital pathology, radiological imaging, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks further characterize interactions among malignant cells, stromal fibroblasts, immune populations, vascular structures, extracellular matrix, signaling pathways, therapeutic targets, and clinical outcomes, thereby enabling systems-level computational reasoning supporting precision oncology.[7]

4. Computational Architecture

Modern computational pathology platforms consist of interconnected computational layers responsible for whole-slide image acquisition, preprocessing, representation learning, multimodal fusion, adaptive learning, predictive analytics, digital twin simulation, and intelligent clinical decision support.[8]

The acquisition layer continuously integrates whole-slide pathology images, radiological imaging, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health

records. Advanced preprocessing pipelines normalize staining variability, harmonize molecular datasets, register multimodal images, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing tissue architecture, molecular biology, imaging phenotypes, physiological function, and longitudinal clinical trajectories. These unified computational representations support diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive learning, and precision pathology.[9]

5. Histopathological Representation Learning

Histopathological representation learning represents one of the greatest strengths of foundation AI models because these systems automatically identify biologically meaningful tissue features without explicit manual annotation. Foundation models learn generalized representations describing cellular morphology, nuclear pleomorphism, mitotic activity, glandular organization, stromal architecture, vascular networks, immune infiltration, fibrosis, necrosis, and tumor heterogeneity across multiple cancer types.[10]

Transformer architectures capture long-range contextual relationships among histological structures distributed across entire whole-slide images, while graph neural networks model spatial interactions among neighboring cells and tissue compartments. These computational representations substantially improve diagnostic classification, tumor grading, biomarker discovery, and prognostic prediction.

Transferable histopathological knowledge learned through foundation models enables rapid adaptation to rare tumor types and previously unseen clinical tasks while reducing dependence on extensive manual annotation.[11]

6. Digital Pathology and Multi-Omics Integration

Comprehensive precision oncology increasingly depends upon integration of digital pathology with genomics, transcriptomics, proteomics,

metabolomics, epigenomics, immunomics, microbiomics, spatial biology, and single-cell sequencing into unified molecular representations of evolving tumor biology.[12]

Foundation AI models utilize multimodal transformers, graph neural networks, biological knowledge graphs, and self-supervised learning to identify latent biological relationships among tissue morphology, molecular pathways, immune responses, metabolic activity, therapeutic targets, and clinical outcomes that remain difficult to detect using isolated analytical approaches.

These integrated computational representations substantially improve biomarker discovery, molecular subtype classification, therapeutic response prediction, systems biology research, and personalized precision medicine while strengthening translational oncology.[13]

7. Tumor Microenvironment Intelligence

The tumor microenvironment comprises malignant cells, immune populations, stromal fibroblasts, endothelial cells, extracellular matrix components, cytokines, chemokines, metabolites, vascular networks, and complex intercellular communication pathways that collectively influence disease progression and therapeutic response.[14]

Foundation AI models integrate computational pathology with spatial biology, radiological imaging, laboratory biomarkers, and longitudinal clinical information using graph neural networks and multimodal transformers to characterize dynamic cellular ecosystems across multiple organizational scales. These computational frameworks identify biologically meaningful cellular neighborhoods, immune niches, stromal remodeling patterns, angiogenic networks, and signaling interactions governing tumor evolution. Comprehensive modeling of the tumor microenvironment substantially improves biomarker discovery, therapeutic stratification, immunotherapy optimization, and translational oncology research.[15]

8. Explainable Computational Pathology

Clinical implementation of computational pathology requires transparent artificial intelligence capable of supporting pathologist

confidence and regulatory approval. Explainable AI enables visualization of tissue regions, cellular structures, glandular organization, immune infiltration, and morphological features contributing to diagnostic predictions through attention heat maps, saliency visualization, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations.[16]

Explainability substantially improves human–AI collaboration by allowing pathologists to validate computational reasoning, recognize algorithmic uncertainty, detect potential errors, and incorporate AI recommendations into routine diagnostic workflows while maintaining clinical responsibility.

Transparent computational pathology therefore strengthens clinician trust, reproducibility, accountability, and safe implementation within precision oncology.[17]

9. Precision Cancer Diagnostics

One of the most clinically significant applications of AI-enabled computational pathology is precision cancer diagnosis through comprehensive integration of histopathological morphology, radiological imaging, molecular biology, laboratory biomarkers, wearable physiological monitoring, medication history, physician documentation, and longitudinal clinical trajectories. Foundation AI models simultaneously analyze heterogeneous biomedical information to classify tumor subtype, predict molecular alterations, estimate therapeutic responsiveness, identify prognostic biomarkers, evaluate treatment-related toxicity, and forecast disease progression while continuously refining predictive accuracy using newly acquired biomedical evidence. These adaptive computational systems establish computational pathology as a central component of next-generation precision cancer diagnostics and personalized oncology.[18][19][20]

10. Digital Twins and Computational Pathology Integration

Digital twin technology represents one of the most transformative applications of AI-enabled computational pathology by creating continuously

evolving virtual representations of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate whole-slide pathology images, serial radiological imaging, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]

Unlike conventional predictive models, digital twins continuously update their computational representations as new histopathological and molecular information becomes available. Integration of computational pathology with virtual patient modeling enables simulation of dynamic tissue remodeling, tumor evolution, immune adaptation, stromal changes, angiogenesis, and therapeutic resistance at microscopic resolution. These intelligent virtual patients allow clinicians to evaluate multiple therapeutic strategies before implementation, optimize treatment sequencing, anticipate mechanisms of resistance, and personalize supportive care according to evolving patient biology.

By combining computational pathology with predictive simulation, digital twins transform precision oncology from retrospective tissue analysis toward proactive and continuously adaptive cancer management.

11. Intelligent Clinical Decision Support

Foundation AI models provide the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting digital pathology, radiological imaging, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, these models synthesize diverse biomedical information into unified computational

representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, histopathological biomarker analyses, molecular interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while facilitating collaboration among pathologists, oncologists, radiologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce information fragmentation, and promote evidence-based personalized cancer management throughout the cancer care continuum.

12. Continuous Learning and Adaptive Computational Pathology

A defining characteristic of foundation AI models is their ability to continuously evolve as new histopathological and biomedical information becomes available. Artificial intelligence incorporates newly digitized pathology slides, serial imaging examinations, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes diagnostic and therapeutic recommendations through iterative evaluation of clinical outcomes. Consequently, computational pathology platforms remain synchronized with evolving tumor biology, changing diagnostic criteria, emerging scientific discoveries, updated clinical guidelines, and diverse patient trajectories. This adaptive computational paradigm transforms pathology into a continuously learning discipline

capable of supporting real-time precision oncology.

13. Federated Computational Pathology Networks

Development of highly generalizable computational pathology foundation models requires access to diverse histopathological datasets representing multiple healthcare systems, pathology laboratories, staining protocols, imaging scanners, molecular technologies, treatment strategies, and patient populations. Federated learning enables collaborative development of computational pathology models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local foundation models using whole-slide pathology images, radiological imaging, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Federated computational pathology ecosystems therefore establish international oncology networks capable of accelerating scientific discovery, improving equitable access to precision diagnostics, and supporting global cancer research while maintaining responsible biomedical data stewardship.

14. Validation, Explainability, and Ethical Governance

Successful implementation of AI-enabled computational pathology requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting pathologist confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP

(Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, tissue heat maps, and counterfactual explanations identifying the histopathological structures, molecular biomarkers, imaging features, physiological variables, and clinical factors responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized slide preparation protocols, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of computational pathology into routine clinical practice.

15. Future Perspectives

Future computational pathology ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, and cloud-native healthcare infrastructure into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate histopathological morphology, molecular biology, radiological imaging, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent pathology ecosystems are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Artificial intelligence-enabled computational pathology represents one of the most significant paradigm shifts in modern oncology by integrating digital pathology, radiology, multi-omics, laboratory biomarkers, digital twins, wearable technologies, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional pathology based primarily on visual interpretation, foundation AI models simultaneously analyze tissue architecture, cellular morphology, molecular biology, imaging phenotypes, laboratory biomarkers, physiological monitoring, and longitudinal clinical trajectories to generate holistic computational representations of evolving tumor biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of computational pathology foundation models to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, AI-enabled computational pathology is expected to become a central computational infrastructure supporting precision cancer diagnostics worldwide.

17. Conclusion

Artificial intelligence-enabled computational pathology is transforming precision cancer

diagnostics by integrating whole-slide pathology, radiological imaging, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and personalized cancer care throughout the disease continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen computational pathology ecosystems, enabling increasingly accurate molecular characterization, predictive clinical decision-making, adaptive therapeutics, continuous disease surveillance, and continuously personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among pathologists, oncologists, radiologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of AI-enabled computational pathology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', *Nature Reviews Clinical Oncology*, 20(4), pp. 267-283.
2. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/345>, DOI: <https://doi.org/10.46121/pspc.52.2.18>
3. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, *Power System Protection and Control*, ISSN: 1674-3415, <https://pspac.info/index.php/dlbh/article/view/388>, DOI: <https://doi.org/10.46121/pspc.51.4.7>
4. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October–December 2024, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/325>, DOI: <https://doi.org/10.46121/pspc.52.4.14>
5. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/343>, DOI: <https://doi.org/10.46121/pspc.52.4.16>
6. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', *npj Precision Oncology*, 7(1), p. 28.
7. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, *Power System Protection and Control*, ISSN: 1674-3415, Article URL: <https://pspac.info/index.php/dlbh/article/view/312>, DOI: <https://doi.org/10.46121/pspc.52.4.13>
8. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', *npj Digital Medicine*, 3(1), p. 136.
9. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor

Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415,

<https://pspac.info/index.php/dlbh/article/view/389>, DOI: <https://doi.org/10.46121/pspc.51.4.8>

10. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.

11. Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.

12. Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.

13. Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.

14. Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.

15. Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.

16. Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

17. Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.

18. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.

19. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.

20. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.

21. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial

intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881

22. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.

23. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.

24. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/321>, DOI: <https://doi.org/10.46121/pspc.51.4.4>

25. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April–June 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/304>, DOI: <https://doi.org/10.46121/pspc.51.2.7>

26. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.

27. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/323>, DOI: <https://doi.org/10.46121/pspc.51.4.5>

28. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January–March 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/303>, DOI: <https://doi.org/10.46121/pspc.52.1.5>



29. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/324>, DOI: <https://doi.org/10.46121/pspc.52.2.14>
30. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/311>, DOI: <https://doi.org/10.46121/pspc.52.2.12>